Priority Research Papers:
The impact of the MYB-NFIB fusion proto-oncogene in vivo
Metrics: PDF 3753 views | HTML 2789 views | ?
Oliver R. Mikse1,2,3, Jeremy H. Tchaicha1,2,3, Esra A. Akbay1,2,3, Liang Chen1,2,3, Roderick T. Bronson4, Peter S. Hammerman1,2,5 and Kwok-Kin Wong1,2,3,6
1 Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, USA
2 Harvard Medical School, Boston, Massachusetts, USA
3 Ludwig Institute for Cancer, Cambridge, Massachusetts, USA
4 Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA
5 The Broad Institute, Cambridge, Massachusetts, USA
6 Belfer Institute for Applied Cancer Science, Boston, Massachusetts, USA
Kwok-Kin Wong, email:
Keywords: MYB-NFIB, adenoid cystic carcinoma, breast, salivary, GEMM
Received: November 30, 2015 Accepted: April 11, 2016 Published: May 18, 2016
Recurrent fusion of the v-myb avian myelobastosis viral oncogene homolog (MYB) and nuclear factor I/B (NFIB) generates the MYB-NFIB transcription factor, which has been detected in a high percentage of individuals with adenoid cystic carcinoma (ACC). To understand the functional role of this fusion protein in carcinogenesis, we generated a conditional mutant transgenic mouse that expresses MYB-NFIB along with p53 mutation in tissues that give rise to ACC: mammary tissue, salivary glands, or systemically in the whole body. Expression of the oncogene in mammary tissue resulted in hyperplastic glands that developed into adenocarcinoma in 27.3% of animals. Systemic expression of the MYB-NFIB fusion caused more rapid development of this breast phenotype, but mice died due to abnormal proliferation in the glomerular compartment of the kidney, which led to development of glomerulonephritis. These findings suggest the MYB-NFIB fusion is oncogenic and treatments targeting this transcription factor may lead to therapeutic responses in ACC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.